PMID- 35429891
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20220531
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 233
DP  - 2022 May
TI  - The genetic deletion and protein expression of PRDM1 and its clinical 
      implications in diffuse large B cell lymphoma: A retrospective cohort study in 
      China.
PG  - 153860
LID - S0344-0338(22)00103-0 [pii]
LID - 10.1016/j.prp.2022.153860 [doi]
AB  - OBJECT: To investigate the clinical implications of the PRDM1 deletion and PRDM1 
      protein expression in Chinese diffuse large B cell lymphoma (DLBCL). MATERIALS 
      AND METHODS: Tumor samples of 199 patients with DLBCL were obtained from the 
      Department of Pathology of Peking University First Hospital between 2008 and 
      2015. The PRDM1 expression was detected by immunohistochemistry (IHC) in all 
      samples. Among them, the PRDM1 deletion was detected in 60 samples by 
      fluorescence in situ hybridization (FISH). The correlations between PRDM1 protein 
      expression and PRDM1 molecular status and clinicopathological features were 
      analyzed. RESULTS: Immunohistochemically, 58 (29.1%) patients were classified as 
      the germinal center B-cell (GCB) subtype, and 141 (70.9%) patients were non-GCB 
      subtype. PRDM1 protein was strongly expressed in 15 (7.5%) patients, weakly 
      expressed in 67 (33.7%) patients, and negative in 117 (26.6%) patients. 
      Heterozygous and homozygous PRDM1 deletions were observed in 28.3% (17/60) and 
      8.3% (5/60) of cases, respectively. The PRDM1 deletion was not significantly 
      correlated with PRDM1 protein expression. Neither the PRDM1 protein expression 
      nor the PRDM1 deletion was significantly associated with most clinicopathological 
      features, including their immunophenotypes according to the Han's algorithm. 
      However, Kaplan-Meier survival analysis showed that heterozygous and/or 
      homozygous PRDM1 deletion but not PRDM1 expression was a poor prognostic factor 
      in the non-GCB group. In addition, there was a positive correlation between PRDM1 
      and c-Myc expression. CONCLUSIONS: Our results suggested that homozygous or 
      heterozygous PRDM1 deletion is a poor prognostic factor for non-GCB DLBCL.
CI  - Copyright (c) 2022 Elsevier GmbH. All rights reserved.
FAU - Nong, Lin
AU  - Nong L
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Zheng, Yalin
AU  - Zheng Y
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Li, Xin
AU  - Li X
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Li, Dong
AU  - Li D
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Liang, Li
AU  - Liang L
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Li, Ting
AU  - Li T
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China. 
      Electronic address: lixiaoting12@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220328
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 138415-26-6 (PRDM1 protein, human)
RN  - EC 2.1.1.- (Positive Regulatory Domain I-Binding Factor 1)
SB  - IM
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - Positive Regulatory Domain I-Binding Factor 1/genetics
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-6/metabolism
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Diffuse large B cell lymphoma
OT  - Genetic deletion
OT  - Lymphoma
OT  - PRDM1
EDAT- 2022/04/17 06:00
MHDA- 2022/05/06 06:00
CRDT- 2022/04/16 20:14
PHST- 2021/08/31 00:00 [received]
PHST- 2022/01/24 00:00 [revised]
PHST- 2022/03/25 00:00 [accepted]
PHST- 2022/04/17 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/04/16 20:14 [entrez]
AID - S0344-0338(22)00103-0 [pii]
AID - 10.1016/j.prp.2022.153860 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2022 May;233:153860. doi: 10.1016/j.prp.2022.153860. Epub 2022 
      Mar 28.